Loading...
To investigate the efficacy, safety, tolerability and time course of response to treatment with intranasal zavegepant for acute migraine attacks, researchers conducted a multicenter, randomized, placebo-controlled, manufacturer-sponsored, phase 3 trial. The coprimary endpoints were pain freedom and freedom from most bothersome symptom at 2 hours after treatment. Adults with migraine attacks with or without aura, of moderate to severe intensity, two to eight times monthly and on fewer than 15 days per month were randomly assigned 1:1 to 10 mg of zavegepant or placebo, stratified by use or nonuse of preventive medications. Participants recorded pain intensity, presence or absence of most bothersome associated symptoms, and functional disabili…